Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®
Novo Nordisk A/S
This trial is conducted in Europe. The aim of this observational study is to evaluate the
change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal
clinical practice conditions.
Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany
Novo Nordisk A/S
This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON
INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when
using Levemir® versus Protaphane® in combination with OADs in daily settings.
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
>To obtain an estimation for both treatment groups of the proportion of patients that reach
the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group.
- Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and
after each period of treatment.
- Incidence of confirmed symptomatic and nocturnal hypoglycemia.
- Incidence of confirmed severe hypoglycemia (< 36mg/dL or need of help to recover).
>Weight variation for each period of treatment.
- Creatinine clearance at baseline and after each period of treatment.
- Overall safety: Incidence of adverse events.
Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation
Medical University of Vienna
The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment
with short acting insulin, applied continuously through an insulin pump, (i) improves
glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers
further β-cell protection, in comparison to the standard of care control group, and the basal
insulin treatment group. In the SAPT-NODAT study, we will employ sensor-augmented
insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic
events. Patients in the SAPT-NODAT study will be followed through 24 months
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.